Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 35 Cambridge Park Drive CAMBRIDGE MA 02140 |
Tel: | N/A |
Website: | https://syros.com |
IR: | See website |
Key People | ||
Conley Chee President, Chief Executive Officer, Director | Jason Haas Chief Financial Officer | Gerald E. Quirk Chief Legal Officer |
David A. Roth Chief Medical Officer | Kristin Stephens Chief Development Officer |
Business Overview |
N/A |
Financial Overview |
For the fiscal year ended 31 December 2023, Syros Pharmaceuticals Inc revenues decreased 33% to $9.9M. Net loss increased 74% to $164.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects FV Adjustments of Financial Investments decrease from $43.2M (income) to $37.3M (expense), Research & Development - Balancing value increase of 1% to $76.7M (expense). |
Employees: | 68 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $38.98M as of Dec 31, 2023 |
Annual revenue (TTM): | $9.94M as of Dec 31, 2023 |
EBITDA (TTM): | -$124.25M as of Dec 31, 2023 |
Net annual income (TTM): | -$164.57M as of Dec 31, 2023 |
Free cash flow (TTM): | -$109.98M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 26,453,891 as of Mar 6, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |